Annual Report

Overview

The report describes Orchid Pharma's FY24 growth, including sales of ₹819 crores and continued expansion in pharmaceutical manufacturing. It highlights Enmetazobactam as an India-originated innovation that received European Medicines Agency clearance and USFDA approval. The BRSR reports 923 employees and quantifies Scope 1 emissions at 339.9385083 metric tonnes of CO2 equivalent and Scope 2 emissions at 41557.47901 metric tonnes of CO2 equivalent.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023-2024
Period: 1 April 2023 – 31 March 2024
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services